Over the three time periods, there was a progressive increase in older age at CBT, adverse cytogenetics of AML, absence of MDS/MPN, early phase at CBT, cryopreserved TNC dose, cryopreserved CD34+ cell dose, MAC regimens, use of non-TBI regimens, and GVHD prophylaxis without MTX. The gene discussed is CD34; the disease is myeloproliferative disorder.